These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 33963858)
21. Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and Naguib MJ; Makhlouf AIA Drug Deliv; 2021 Dec; 28(1):1301-1311. PubMed ID: 34176378 [TBL] [Abstract][Full Text] [Related]
22. Rubusoside As a Multifunctional Stabilizer for Novel Nanocrystal-Based Solid Dispersions with a High Drug Loading: A Case Study. Liu Y; Wu Z; Chen Y; Guan Y; Guo H; Yang M; Yue P J Pharm Sci; 2024 Mar; 113(3):699-710. PubMed ID: 37659720 [TBL] [Abstract][Full Text] [Related]
23. Loratadine oral bioavailability enhancement via solid dispersion loaded oro-dispersible films: Formulation, characterization and pharmacokinetics. Islam N; Khan NU; Razzaq A; Menaa F; Khan ZU; Hussain A; Rehman SU; Iqbal H; Ni J Colloids Surf B Biointerfaces; 2023 Oct; 230():113526. PubMed ID: 37647750 [TBL] [Abstract][Full Text] [Related]
24. Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release. El-Hammadi M; Awad N AAPS PharmSciTech; 2012 Mar; 13(1):53-8. PubMed ID: 22101967 [TBL] [Abstract][Full Text] [Related]
25. Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a Novel Method of Continuously Preparing Nanocrystal Solid Dispersions. Ye X; Patil H; Feng X; Tiwari RV; Lu J; Gryczke A; Kolter K; Langley N; Majumdar S; Neupane D; Mishra SR; Repka MA AAPS PharmSciTech; 2016 Feb; 17(1):78-88. PubMed ID: 26283197 [TBL] [Abstract][Full Text] [Related]
26. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Jiang T; Han N; Zhao B; Xie Y; Wang S Drug Dev Ind Pharm; 2012 Oct; 38(10):1230-9. PubMed ID: 22229827 [TBL] [Abstract][Full Text] [Related]
27. Preparation of Loratadine Orally Disintegrating Tablets by Semi-solid Extrusion 3D Printing. Yi S; Xie J; Chen L; Xu F Curr Drug Deliv; 2023; 20(6):818-829. PubMed ID: 36221886 [TBL] [Abstract][Full Text] [Related]
28. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption. Sarnes A; Kovalainen M; Häkkinen MR; Laaksonen T; Laru J; Kiesvaara J; Ilkka J; Oksala O; Rönkkö S; Järvinen K; Hirvonen J; Peltonen L J Control Release; 2014 Apr; 180():109-16. PubMed ID: 24566254 [TBL] [Abstract][Full Text] [Related]
29. PREPARATION AND CHARACTERIZATION OF ORALLY DISINTEGRATING LORATADINE TABLETS MANUFACTURED WITH CO-PROCESSED MIXTURES. Amelian A; Szekalska M; Wilczewska AZ; Basa A; Winnicka K Acta Pol Pharm; 2016; 73(2):453-60. PubMed ID: 27180438 [TBL] [Abstract][Full Text] [Related]
30. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Ige PP; Baria RK; Gattani SG Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990 [TBL] [Abstract][Full Text] [Related]
31. Preparation, characterization and pharmacokinetics of cyadox nanosuspension. Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446 [TBL] [Abstract][Full Text] [Related]
32. Design and characterization of nanocrystal formulations containing ezetimibe. Gulsun T; Gursoy RN; Oner L Chem Pharm Bull (Tokyo); 2011; 59(1):41-5. PubMed ID: 21212545 [TBL] [Abstract][Full Text] [Related]
33. Enhanced oral bioavailability of glycyrrhetinic acid via nanocrystal formulation. Lei Y; Kong Y; Sui H; Feng J; Zhu R; Wang W Drug Deliv Transl Res; 2016 Oct; 6(5):519-25. PubMed ID: 27206446 [TBL] [Abstract][Full Text] [Related]
34. In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative. Xu D; Ni R; Sun W; Li LC; Mao S Drug Dev Ind Pharm; 2015 Apr; 41(4):552-9. PubMed ID: 24495272 [TBL] [Abstract][Full Text] [Related]
35. Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes. Szabados-Nacsa A; Sipos P; Martinek T; Mándity I; Blazsó G; Balogh Á; Szabó-Révész P; Aigner Z J Pharm Biomed Anal; 2011 May; 55(2):294-300. PubMed ID: 21316895 [TBL] [Abstract][Full Text] [Related]
36. The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: In vitro-in vivo correlation of nanocrystals. Imono M; Uchiyama H; Yoshida S; Miyazaki S; Tamura N; Tsutsumimoto H; Kadota K; Tozuka Y Eur J Pharm Biopharm; 2020 Jan; 146():84-92. PubMed ID: 31816392 [TBL] [Abstract][Full Text] [Related]
37. Development and evaluation of a novel modified-release pellet-based tablet system for the delivery of loratadine and pseudoephedrine hydrochloride as model drugs. Zeeshan F; Bukhari NI AAPS PharmSciTech; 2010 Jun; 11(2):910-6. PubMed ID: 20496016 [TBL] [Abstract][Full Text] [Related]
38. Solubility enhancement of desloratadine by solid dispersion in poloxamers. Kolašinac N; Kachrimanis K; Homšek I; Grujić B; Ðurić Z; Ibrić S Int J Pharm; 2012 Oct; 436(1-2):161-70. PubMed ID: 22772487 [TBL] [Abstract][Full Text] [Related]
40. Dissolution evaluation in vitro and bioavailability in vivo of self-microemulsifying drug delivery systems for pH-sensitive drug loratadine. Li H; Tan Y; Yang L; Gao L; Wang T; Yang X; Quan D J Microencapsul; 2015; 32(2):175-80. PubMed ID: 25413271 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]